Loading

Annals of Clinical and Experimental Hypertension

Predictors of Microalbuminuria among Hyperuricemia with Hypertension Patients

Research Article | Open Access

  • 1. Division of Cardiovascular Medicine, University of Toho, Japan
+ Show More - Show Less
Corresponding Authors
Hidehiko Hara, Division of Cardiovascular Medicine, Toho University, Ohashi Medical Center,2-17-6 Ohashi, Meguro-ku, Tokyo, Japan, 153-8515, Tel : 81-3-3468-1251; Fax 81-3-3468-1269
Abstract

Recently, the link between urinary albumin excretion and increased incidence of cardiovascular mortality has been demonstrated. Besides, clinical trials demonstrated the reduction of urinary albumin extraction during treatment translated into a reduction on cardiovascular event. On the other hand, hyperuricemia has been focused as one of cardiovascular events. However, the reported prevalence of microalbuminuria (MAU) in patients with hyperuricemia with hypertension is unknown.

Aims and methods: We conducted a cross-sectional single center study investigating the prevalence of urinary albumin excretion in patients with hyperuricemia and essential hypertension as a sub-study of the Jonan Irbesartan Microalbuminuria Study (JIMS). A total of 266 outpatients with hyperuricemia with essential hypertension were enrolled into this study.

Results: Mean systolic and diastolic blood pressure was 129.5±13.3mmHg and 74.0±9.3 mmHg respectively. The prevalence of MAU was 45.5% in this cohort. Predictive factors of the presence of MAU were age and diabetes mellitus, (OR; 1.023and 1.917, respectively).

Conclusions: The present study showed that the prevalence of MAU was >45% in hyperuricemia with hypertensive patients, even though blood pressure was relatively well controlled. Additionally, age and presence of diabetes mellitus were predictive factors of the presence of MAU. These findings may suggest that there is a substantial number of essential hypertension and hyperuricemia patients with MAU, and the importance of strict control of these factors for the improvement of the prognosis.

Citation

Hara H, Nakamura M (2015) Predictors of Microalbuminuria among Hyperuricemia with Hypertension Patients. Ann Clin Exp Hypertension 3(1): 1018.

Keywords

•    Albuminuria
•    Hypertension
•    Hyperuricemia
•    Diabetes mellitus

ABBREVIATIONS

CKD: Chronic Kidney Disease; ESRD: End Stage Renal Disease (MAU): Microalbuminuria; JIMS: Jonan Irbesartan Microalbuminuria Study; BMI: Body Mass Index MDRD: Modification Of Diet In Renal Disease; GFR: Glomerular Filtration Rate JDS: Japan Diabetes Society; ARB: Angiotensin Receptor Blocker; ACEI: Angiotensin-Converting-Enzyme Inhibitor; Hb: Hemoglobin; BUN: Blood Urea Nitrogen; Cr: Creatinine

INTRODUCTION

Recent epidemiological studies have shown that chronic kidney disease (CKD) is an independent risk factor for cardiovascular mortality and morbidity, and shown that the population of CKD has growing recently [1-3]. Because ischemic heart disease remains main cause of mortality, much attentions have to be paid for the awareness and understanding of CKD. One of the important points of the concept of CKD is the fact that the risk of cardiovascular disease increases not only at the end stage renal disease (ESRD) but at the early stage of CKD [2,4,5]. Therefore, early detection and appropriate treatment for CKD could be clinically meaningful. It seems to be reasonable to consider that treatment should start at an earlier stage, leading to a better outcome. However early stage of CKD is unlikely to be diagnosed timely, and easily overlooked. Numerous studies demonstrated that microalbuminuria (MAU), a powerful predictor of glomerular injury, is also a predictor for the development of renal and cardiovascular complications [6-10]. This association is independent of the widely accepted cardiovascular risk factors. Furthermore, the LIFE study demonstrated that the reduction of urinary albumin extraction during treatment translated into a reduction in cardiovascular event [11]. However, reported prevalence of MAU in studied population is highly variable among studies ranging 7 to 58.4% [12-14]. These differences may be explained by prescribed drugs, and researched population. Especially, recent progress in pharmacological therapy showing beneficial effects of blood pressure control may affect the favorite effects on the secretion of MAU.

On the other hand, some data suggest that hyperuricemia is associated with cardiovascular disease risk factors and cardiovascular disease, often being a predictor of incident events [15].

Therefore, we tried to investigate the prevalence and risk factors for the presence of MAU in Japanese hyperuricemia with hypertension patients under the current medical treatment.

METHODS AND SUBJECTS

Jonan (Irbesartan (Microalbuminur (Study (JIMS) investigators conducted a cross-sectional multicenter cohort study looking at the prevalence of urinary albumin excretion in patients with treated essential hypertension under current practice [16]. This study is sub analysis of the JIMS and we conducted a cross-sectional single center study investigating the prevalence of urinary albumin excretion in patients with hyperuricemia and essential hypertension. Consecutive patients with hypertension who had already been pointed out hyperuricemia, visited our hospital were enrolled. This study was started in July 2009. By the end of August 2010, a total of 266hyperuricemia with essential hypertension patients had been enrolled into this study. Exclusion criteria were secondary hypertension, renal insufficiency with plasma creatinine concentration > 2.0 mg/dl, and persistent macroproteinuria by conventional dipstick test of spot urine sample (positive ?2). Patients with acute fever, concomitant urinary tract infection, having undertaken strenuous physical activity within preceding 24 hours as well as female participants who were pregnant or menstruation were also excluded due to the likely presence of false-positive results. Systolic and diastolic blood pressure were measured by using a mercury manometer, placed on the right arm of seated subjects who had rested in a sitting position for at least 5 min before measurement. Hypertension was defined as an average blood pressure >140/90 mmHg on at least two different occasions during routine examination. Diabetes was defined as follows; subjects who were receiving oral hypoglycemic or insulin treatment were defined as treated diabetes. Subjects with fasting blood sugar >126mg/dl, random blood sugar >200mg/dl or HbA1c value >6.1% were also defined as diabetic. Hypercholesterolemia was defined as total cholesterol >240 mg/ dl. Obesity was defined as a body mass index (BMI) >25kg/m2 , calculated as body weight in kilograms divided by the square of the height in meters. Hyperuricemia was defined as follows; serum uric acid > 7.0 mg/dl or past history of gout or under medical treatment was defined as hyperuricemia. This study was approved by the medical ethics committee (number 21-5) and all the patients gave informed consent.

Laboratory findings

Serum creatinine levels were measured by enzymatic method. Glomerular filtration rate (GFR) was estimated from adjusted serum creatinine using the simplified equation developed from the Modification of Diet in Renal Disease (MDRD) study as follows. GFR (ml/min/1.78M2 ) =186.3×(serum creatinine) 1.154×age0.203× 0.742 for female subjects [17]. Freshly voided urine was obtained and dip stick test of urine was done by CLINTEK® Microalbumin 2 (Siemens Healthcare Diagnostics Inc., Erlangen, Germany). Proteinuria was evaluated semi quantitatively (-, ± and +). The CLINTEK urinary chemistry analyzer is a portable reflectance photometer which is highly sensitive, purely chemical albumin test strip method based on dye binding by albumin. This urinary dip reagents strip provides the detection of albumin concentration from 10 to 150 mg/l, and also allows simultaneous urinary creatinine concentration [18].

Statistical analysis

Continuous variables were expressed as mean±standard deviation and categorical data were presented as frequencies. For comparisons between groups, we used Student’s t-test to evaluate difference in means and χ2 tests to evaluate the differences in proportions. To test the independent relationship between MAU and variables, potential factors was selected by univariate regression analysis, and selected variables were assessed in a multiple logistic regression analysis model. All statistical analysis was performed using the software of SPSS12.0 (SPSS Inc, Chicago, IL, US). A significant difference was defined as p<0.05.

Table 1: Baseline Patient Demographics.

(n=226)  
Age (years) 71.010.9
Male (%) 171(64.3)
Height (cm) 161.0±8.8
Body weight (kg) 3.1±12.2
BMI (kg/m2) 24.2±3.8
Systolic BP (mmHg) 129.5±13.3
Diastolic BP (mmHg) 74.0±9.3
Laboratory findings  
WBC (μl) 6406±1621
Hb (g/dL) 13.0±1.9
Hct (%) 39.5±4.9
PLT(x104/μl) 20.7±6.0
eGFR (mL/min/1.73m2) 54.0±18.7
TP (g/dl) 7.6±0.6
AST (IU/L) 23.6±10.2
ALT (IU/L) 21.0±12.6
LDH (IU/L) 433.2±86.3
γGTP (IU/L) 27.2±34.9
BUN (mg/dl) 19.3±9.3
Cr (mg/dl) 1.10±0.55
UA (mg/dl) 6.4±1.3
T-CHO (mg/dl) 178.7±31.7
TG (mg/dl) 144.2±77.6
HDL-CHO (mg/dl) 55.3±14.3
LDL-CHO (mg/dl) 97.3±27.3
GLU (mg/dl) 120.2±35.9
HbA1c (%; JDS) 5.7±0.6
CKD staging  
CKD stage1 (eGFR?90) 7(2.6%)
CKD stage2 (60?eGFR 90) 100(37.6)
CKD stage3 (30?eGFR 60) 132(49.6)
CKD stage4 (15?eGFR 30) 24(9.0%)
CKD stage5 (eGFR 15) 3(1.1%)
Medical treatments  
CB 161(60.5)
ARB 164(61.6)
ACEI 69(25.9)
Diuretics 75(28.2)
Beta blocker 101(38.0)
Alfa blocker 29(10.9)
Allopurinol 124(46.6)
Sulfonylurea 24(9.0)
Metformin 13(4.9)
Statin 147(55.3)

BMI: Body Mass Index; BP: Blood Pressure; WBC: White Blood Cell; Hb: Hemoglobin; Hct: Hematocrit; PLT: Platelet; Egfr : Estimated Glomerular Filtration Rate; TP: Total Protein; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; LDH: Lactate Dehydrogenase; Γgtp: GammaGlutamyltranspeptidase; BUN: Blood Urea Nitrogen; Cr: Creatinine; UA: Uric Acid; T-CHO: Total Cholesterol; TG: Triglyceride; HDL-CHO: High Density Lipoprotein Cholesterol; LDL-CHO: Low Density Lipoprotein Cholesterol; GLU: Glucose; Hba1c: Hemoglobin A1c; JDS: Japan Diabetes Society; CKD: Chronic Kidney Disease;CB: Calcium Channel Blocker; ARB: Angiotensin Receptor Blocker; ACEI: Angiotensin Converting Enzyme Inhibitor

RESULTS

Patients’ demographics

A total of 226 patients were enrolled in the present study. Registered patients demographics are shown in (Table1). Mean age was 71.0±10.9 years, and male was 64.3%. Mean systemic blood pressure was 129.5±13.3/74.0±9.3 mm Hg, and obesity with BMI>25kg/m2 was 33.6 %. Mean HbA1c (JDS value: Japan Diabetes Society) was 5.7±0.6 and mean uric acid was 6.4±1.3 mg/dl. The majority of patients were prescribed with angiotensin receptor blocker (ARB; 61.7%) or calcium channel blocker (60.5%). About half of patients (46.6%) were prescribed allopurinol for hyperuricemia.

MAU was prevalent across all age group and the proportion of subjects with MAU increased with each increase in age and CKD staging (Figure 1, 2).

Predictors for MAU

Table 2 demonstrated patient’s profile of subjects with prevalent MAU. There was a statistical significant difference between MAU + and – group regarding age, systolic blood pressure, eGFR and level of HbA1c. However, there was no significant difference on the prevalence of MAU among patients with ARB, angiotensin-converting-enzyme inhibitor (ACEI), or other anti-hypertensive agent usage. Regarding the relationship between the prevalence of MAU and vascular events, the existence of ischemic heart disease were prone to have positive MAU. Moreover, peripheral artery disease which is in the advanced arteriosclerotic stage reveals more positive MAU, and significant difference. Using a univariate logistic regression analysis, following factors were revealed to be associated with the excretion of MAU; age, systolic blood pressure, eGFR, BUN, Cr, HbA1c, and presence of diabetes mellitus, dyslipidemia and peripheral artery disease (Table 3). Multiple logistic regression analysis identified that systolic blood pressure and presence of diabetes was independent factors. The risk of MAU was increased 1.023 times with each 1mmHg increase of systolic blood pressure.

Table 2: Predictors for MAU.

  MAU (-) MAU (+) p value
Total number (%) 145(54.5) 121(45.5)  
Age (years) 69.2±11.7 73.1±9.4 0.0031
male gender(%) 96(66.2) 75(62.0) 0.4741
Body Mass Index 24.4±3.4 24.0±4.3 0.4153
systolic BP(mmHg) 127.7±13.9 131.6±12.2 0.0163
diastolic BP 74.6±9.9 73.2±8.6 0.2171
laboratory findings      
eGFR (ml/ min/1.78m2 ) 57.2±17.8 50.1±19.1 0.0021
AST (IU/L) 23.8±11.0 23.4±9.1 0.7803
ALT (IU/L) 20.9±12.9 21.0±12.3 0.9813
BUN (mg/dl) 18.1±9.0 20.4±9.6 0.0338
Cr (mg/dl) 1.02±0.37 1.20±0.60 0.0035
Uric acid (mg/dl) 6.6±1.4 6.3±1.2 0.0659
Glucose (mg/dl) 117±32 124±4040 0.1199
HbA1c (JDS) 5.6±0.6 5.8±0.7 0.0276
medication      
CB 55.9% 66.1% 0.0884
ARB 59.3% 64.5% 0.3894
ACEI 22.1% 30.6% 0.1149
Diuretics 28.3% 28.1% 0.9746
Beta blocker 38.6% 37.2% 0.8108
vascular events      
IHD 44.8% 55.4% 0.0868
CVD 18.6% 17.4% 0.7893
PAD 6.2% 14.1% 0.0320
comorbidities      
DM 31.0% 46.3% 0.0107
DL 80.0% 69.4% 0.0467

BP: Blood Pressure; GFR: Glomerular Filtration Rate; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; BUN: Blood Urea Nitrogen; Cr: Creatinine; JDS: Japan Diabetes Society; CB: Calcium Channel Blocker; ARB: Angiotensin Receptor Blocker; ACEI: Angiotensin Converting Enzyme Inhibitor; IHD: Ischemic Heart Disease; CVD: Cerebrovascular Disease; PAD: Peripheral Artery Disease; DM: Diabetes Mellitus; DL: Dyslipidemia

DISCUSSIONS

The present study was observational study of patients with treated hypertension with hyperuricemia in the real world practice in Japan. The main findings of the present study include 1) the prevalence of albuminuria was >45%. 2) Independent predictive factors of the excretion of MAU were systolic blood pressure and diabetes mellitus. Because it has been shown that albuminuria is more sensitive than proteinuria in detecting CKD, screening program to identify the disease before clinical phase could be meaningful, though there have been no studies on the direct comparison between proteinuria and MAU in terms of utilities.

The prevalence of MAU

The detection of MAU was as high as 46% in the present study. This finding may suggest that the early stage of CKD was actually overlooked and under- diagnosed clinically. Reported prevalence of MAU in hypertensive population absolutely exceeds those in general population [12-14,19-21]. However, the prevalence rate in hypertensive population was highly variable among studies within range of 26.6% - 58.4% [14,20,21].

Several factors could affect the results of investigations. Aging is recognized as independent risk factor for renal disease due to glomerular ischemia secondary to the change in renal blood flow that occurs with aging. In addition, it has been demonstrated that the prevalence of MAU increases with age [13,14]. Mean age of the present cohort was around 70 years old, and the studied population was older than those of previous studies. A 38.0% of enrolled population was diabetic, whereas in other studies diabetic patients were excluded [22,23]. Furthermore, hypertensive patients with known atherosclerotic disease were included in the present study. Thus, the current cohort is likely to represent hyperuricemic hypertensive population in real world practice. On the other hand, mean blood pressure was 129.5/74.0 mmHg in our cohort. In i-SERACH study reporting 58.4% of albuminuria, mean blood pressure was 149.2±20.2mmHg, and 76.8 % of uncontrolled hypertensive patients were included [14]. Therefore, 45.5% of albuminuria in our relatively well controlled hypertensive population suggests remarkably high prevalence of MAU in current practice because presumably hyperuricemia may be influential. Another possible explanation is the differences in the method including collection of urine sample, and diagnosis criteria might affect the outcomes in our series. Besides, Weir et al reported 40% prevalence of MAU in Asian hypertensive diabetic patient [24]. Konta et al also demonstrated the higher prevalence of MAU in Japanese general population [13]. Therefore, there is a possibility that Asian population might be susceptible to MAU.

Predictors of MAU

The results of the present study also demonstrated that within the hyperuricemia and hypertensive patients, the risk of developing MAU was significantly greater if patients had higher blood pressure as well as the presence of diabetes. These data suggest strong and independent influences of systemic arterial pressure on urinary albumin extraction, and are well consistent with a recent report showing development of MAU linked to insufficient blood pressure control in essential hypertension [25,26].

Furthermore, recent investigations demonstrated strict blood pressure control reduces proteinuria and prevent progression of ESRD [11,27-29]. In this analysis, mean systolic blood pressure of patients with positive and negative MAU are 131.6±12.2/73.2±8.6 mmHg and 127.7±13.9/74.6±9.9 mmHg respectively. Thus, the difference of mean systolic blood pressure between 2 groups was only limited to 3.9 mmHg. These findings confirm the importance of strict control of blood pressure to prevent the glomerular injury, and also are likely to strongly suggest that blood pressure and glucose control should be managed more strictly at early phase of hypertension.

It has been reported that certain class of antihypertensive medications such as angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists reduce proteinuria [22,27- 29]. However, the difference of renal preservation effect among drugs was unclear in this study. Because the information about doses and the duration of prescribed medication and duration of hypertensive status were not available in this study.

Other important contributions to increased risk of MAU were the comorbidity of diabetes. Diabetes is well-known predictor for developing proteinuria, and it has been shown that strict control of glucose level can reduce and prevent proteinuria [30,31]. These findings are consistent with the present study. MAU was more frequently observed in polyvascular disease. It has been shown that the lower ankle-brachial index is the risk of cardiovascular complication is greater. Moreover, in REACH registry, the incidence of future cardiovascular event was higher in patients with peripheral artery disease compared to those with other arteriosclerotic disease [32]. Taken together, the proposed hypothesis that MAU is a marker of more generalized and wide spread endothelial dysfunction and atherosclerosis is likely to consistent with the present study. Moreover, the view that MAU is an independent for atherosclerotic disease, and carries prognostic information beyond that of other risk factors may be supported.

Table 3:

Variable   OR 95%CI P-value
Age 1.010 0.979-1.043 0.5268
Systolic BP 1.023 1.002-1.045 0.0298
eGFR 0.991 0.972-1.011 0.3755
DM 1.917 1.089-3.376 0.0242
DL 0.575 0.309-1.070 0.0809
PAD 2.319 0.904-5.951 0.0801

OR: Odds Ratio; CI: Confidence Interval; BP: Blood Pressure; GFR: Glomerular Filtration Rate; DM: Diabetes Mellitus; DL: Dyslipidemia; PAD: Peripheral Artery Disease

LIMITATIONS

There are several limitations we should mention. First of all, this is an observational study. There may be selection bias in our study population. Thus, generalization of present study outcomes may be somewhat limited. Besides, we believe that enrollment of consecutive out-patients represents the actual accurate findings. Second, the urine check was limited to the once, which did not completely confirm to the requirement of multiple urine collections for MAU [33]. However, Brantsma et al revealed that single measurement has enough power to predict the future prognosis [34]. Third, , the GFR estimates using the simplified prediction equation derived from the MDRD study might not be sufficiently correct, because it is based on the single blood sample. However, this equation is considered to be the most precise one [35]. Finally, no information regarding the severity or duration of hypertension was obtained in present study.

CONCLUSIONS

The present study showed that the prevalence of MAU was >45% in hyperuricemia among hypertensive patients, even though blood pressure was relatively well controlled. In addition, predictive factors of the presence of MAU were systolic blood pressure, and presence of diabetes. These findings may suggest that early detection and awareness of this sensitive marker is quite important for the management of hyperuricemic and hypertensive patients in real world practice.

ACKNOWLEDGMENTS

We appreciate the Associations for Establishment of Evidence in Interventions for financial supports.

REFERENCES

1. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005; 68: 228- 236.

2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112-119.

3. Levey AS, Beto JA, Coronado BE, Eknoyan G, Foley RN, Kasiske BL, et al. Controlling the epidemic of cardiovascular disease in chronic renaldisease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis1998; 32:853-906.

4. Culleton BF, Hemmelgarn BR. Is chronic kidney disease a cardiovascular disease risk factor? Semin Dial. 2003; 16: 95-100.

5. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 28; 108: 2154-2169. 

6. Jager A, Kostense PJ, Ruhe HG, Heine RJ, Nijpels G, Dekker JM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality among hypertensive subjects; five-year follow-up of the Hoorn study. AtheriosclerThrombVascBiol 1999; 19: 617-624.

7. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ. 1996; 313: 779-784.

8. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286: 421-426.

9. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984; 310: 356-360.

10. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, et al. Micoralbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001; 249: 519- 526.

11. Ibsen H, Olsen MH, Wachtell K, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Reduction inalbuminuria translates to reduction in cardiovascular events in hypertensivepatients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.

12. De Jong PE, Hillege HL, Pinto-Sietsma SJ, de Zeeuw D. Screening for microalbuminuria in the general population: a tool to detect subjects at risk for progressive renal failure in an early phase? Nephrol Dial Transplant. 2003; 18: 10-13.

13. Konta T, Hao Z, Abiko H, Ishikawa M, Takahashi T, Ikeda A, et al. Prevalence and risk factor analysis of microalbuminuria in Japanese general population: the Takahata study. Kidney Int. 2006; 70: 751- 756.

14. Böhm M, Thoenes M, Danchin N, Bramlage P, La Puerta P, Volpe M. Association of cardiovascular risk factors with microalbuminuria in hypertensive individuals: the i-SEARCH global study. J Hypertens. 2007; 25: 2317-2324.

15. Borghi C, Verardi FM, Pareo I, Bentivenga C, Cicero AF. Hyperuricemia and cardiovascular disease risk. Expert Rev Cardiovasc Ther. 2014; 12: 1219-1225.

16. Hara H, Kougami K, Shimokawa K, Nakajima S, Nakajima R, Nakamura R, et al. The prevalence and risk factors of microalbuminuria in hypertensive patients under current medical treatment. Intern Med. 2014; 53: 1275-1281.

17. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, et al. Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. ClinExpNephrol 2007; 11: 45-50.

18. Sasaki M, Pugia MJ, Parker DR, Kuromoto K, Furukawa I, Konishi I. Measurement of the albumin content of urinary protein using dipsticks. J Clin Lab Anal. 1999; 13: 246-250.

19. Tomura S, Kawada K, Saito K, Lin YL, Endou K, Hirano C, et al. Prevalence of microalbuminuria and relationship to the risk of cardiovascular disease in the Japanese population. Am J Nephrol. 1999; 19: 13-20.

20. Munakata M, Nunokawa T, Yoshinaga K, Toyota T; J-TOPP Study Group. Brachial-ankle pulse wave velocity is an independent risk factor for microalbuminuria in patients with essential hypertension- -a Japanese trial on the prognostic implication of pulse wave velocity (J-TOPP). Hypertens Res. 2006; 29: 515-521. 

21. Boersma C, Postman MJ, Visser ST, Atthobari J, de Joung PE, de Jongvan den Berg LTW, et al. Baseline albuminuria predicts the efficacy of blood pressure-lowering drugs in preventing cardiovascular events. Br J Clin Pharmacol 2008; 1-10.

22. Brantsma AH, Atthobari J, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. What predicts progression and regression of urinary albumin excretion in the nondiabetic population? J Am Soc Nephrol. 2007; 18: 637-645.

23. Gatzka CD, Reid CM, Lux A, Dart AM, Jennings GL. Left ventricular mass and microalbuminuria: relation to ambulatory blood pressure. Hypertension Diagnostic Service Investigators. Clin Exp Pharmacol Physiol. 1999; 26: 514-516.

24. Weir MR. Albuminuria predicting outcome in diabetes: incidence of microalbuminuria in Asia-Pacific Rim. Kidney Int Suppl. 2004; S38-39.

25. Asselbergs FW, Diercks GFH, Hillege HL, van Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809-2816.

26. Pascual JM, Rodilla E, Gonzalez C, Pérez-Hoyos S, Redon J. Long-term impact of systolic blood pressure and glycemia on the development of microalbuminuria in essential hypertension. Hypertension. 2005; 45: 1125-1130.

27. Yusuf S, Sleight G, Pogue J, Bosch J, Davies R, Dagenais G. The Heart Outcomes prevention evaluation study investigators. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-153.

28. Heart outcomes Prevention evaluation (HOPE) study investigators. Effect of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus. Results of HOPE study and MICROHOPE sub study. Lancet 2000; 355: 253-259.

29. Parving HH, Lehnert H, Bochner-Mortensen J,Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.

30. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342:381- 389.

31. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 1998; 317: 703-713.

32. Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Röther J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197-1206.

33. Levey AS, Eckardt KU, Tsukamoto Y, Levin A, Coresh J, Rossert J, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-2100.

34. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT. Prevend Study Group. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol. 2008; 19: 1785-1791.

35. Bakris G. Proteinuria: a link to understanding changes in vascular compliance? Hypertension. 2005; 46: 473-474.

Hara H, Nakamura M (2015) Predictors of Microalbuminuria among Hyperuricemia with Hypertension Patients. Ann Clin Exp Hypertension 3(1): 1018.

Received : 30 Dec 2014
Accepted : 14 Jan 2015
Published : 17 Jan 2015
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
Annals of Vascular Medicine and Research
ISSN : 2378-9344
Launched : 2014
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X